Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
113
-
Total 13F shares, excl. options
-
57M
-
Shares change
-
+799K
-
Total reported value, excl. options
-
$104M
-
Value change
-
+$1.82M
-
Put/Call ratio
-
0.8
-
Number of buys
-
59
-
Number of sells
-
-36
-
Price
-
$1.83
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q1 2024
132 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q1 2024.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 113 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 57M shares
of 236M outstanding shares and own 24.12% of the company stock.
Largest 10 shareholders include Alerce Investment Management, L.P. (13.2M shares), VANGUARD GROUP INC (8.23M shares), ACADIAN ASSET MANAGEMENT LLC (5.31M shares), RENAISSANCE TECHNOLOGIES LLC (3.65M shares), MILLENNIUM MANAGEMENT LLC (3.27M shares), BlackRock Inc. (2.54M shares), Qube Research & Technologies Ltd (2.26M shares), GEODE CAPITAL MANAGEMENT, LLC (1.82M shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (1.76M shares), and JACOBS LEVY EQUITY MANAGEMENT, INC (1.64M shares).
This table shows the top 113 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.